Welcome to the new and improved CBD-Intel US state law regulatory tracker, updated every month and exclusively focused on state law. This interactive map allows you to search for states, zoom in and out from the map, view more than one regulatory area at a time, pan the map and select multiple states to compare regulations.
All the stories from the CBD-Intel weekly global regulatory Live Alerts in one user-friendly database, updated every month.
This regulatory tool consolidates all of our global regulatory Live Alerts since they were launched in May 2019, collected in Excel database format, allowing you to filter information by date and country.
CBD-Intel’s newly upgraded global regulatory tracker, updated every month, now offers a deeper analysis of each regulatory area.
Use the tabs at the top of the map to select a specific regulatory field and click on an individual country to bring up much more detail in the panel below, including links to legislation and CBD-Intel’s coverage of that market.
The key below the map indicates the level of regulation for the selected country and regulatory field based on our in-house analysis.
The Marijuana Opportunity Reinvestment and Expungement (MORE) Act was, of course, always more about cannabis than hemp-derived CBD specifically. And, as previously stated, its chances of passing were slim to none.
There does not seem to be much point in continuing to try to force through bills – particularly given that the Republican-controlled senate and presidency opposes any measures and the limited timeframe before the end of the legislative session.
The US House of Representatives is expected to hold a historic vote this month on a comprehensive cannabis reform bill that supporters embrace for not only decriminalising marijuana but correcting injustices
The trade body for hemp and CBD in Ireland has accused the Irish government of working in silos and said its lack of intra-governmental communication as well as consultation with stakeholders could lead to the end of the industry in the country
Enforcement activity against food, drink and dietary supplement products placed on the market containing CBD continues despite the inability of companies to proceed with novel food applications due to the EC’s questions over whether CBD constitutes a narcotic under the 1961 UN Single Convention on Narcotics.
Several major developments have all happened at the same time for novel foods. Perhaps most importantly, one of the European Commission’s departments – the Directorate-General for Health and Food Safety – has said it is holding sending any further non-synthetic CBD applications to the European Food Safety Authority for evaluation until it has determined whether CBD technically falls under the definition of a narcotic according to the 1961 UN Single Convention on Narcotic Drugs.
Countries in South America are becoming increasingly important markets for CBD, as the ink dries on a deal to distribute medical cannabis products in Brazil, where a change in regulatory policy has opened up trade
UK companies that are struggling and in need of assistance because of due to lockdown rules in the face of the COVID-19 pandemic have several options to choose from, depending on their size and their needs
The French government’s ban on the importing of CBD products conflicts with European law on free movement of goods, EU advocate general Evgeni Tanchev says, in an opinion that could have EU-wide implications
Further advances towards the legalisation of cannabis in Mexico have been delayed by a government shutdown due to the COVID-19 pandemic, with a new deadline for legislation set by the country’s Supreme Court
Four months after Zambia legalised the production and export of cannabis, no one has yet been able to take advantage because of the high cost of licensing fees – and some confusion remains about what is allowed
Companies are beginning to show interest in Kazakhstan ahead of an anticipated liberalisation of cannabis laws they hope will allow the cultivation and production of hemp products for medical, food and other purposes
Legislative efforts will continue to push for cannabinoid liberalisation in the Philippines – despite recent comments that approval in principle of the epilepsy drug Epidiolex would be sufficient to cover most matters
A coalition of organisations linked to the US hemp market has released the first part of a series of policy recommendations – while one CBD firm has been referred to the US Federal Trade Commission over extravagant health claims
Germany’s Federal Institute for Risk Assessment (BfR) recently issued a warning on e-liquids that it believed to be containing synthetic cannabinoids, after at least eight teenagers suffered medical complications from an as yet unconfirmed source
CBD-Intel provides impartial, independent and premium market and regulatory analysis, legal tracking, and quantitative data for the cannabidiol (CBD) sector worldwide. Most content is available to subscribers only.
Do the Novel Food regulations in Europe affect your business?
CBD as a Novel Food: the future for edibles in Europe
This new CBD-Intel report examines key aspects and drivers of the edibles market itself before looking in detail at the Novel Food regulations, both at EU level and in non-EU markets: notably the UK, as well as Switzerland and Norway.
Questions it considers and answers include whether CBD really is novel, whether approvals are likely to be generic or applicant-specific, how the Novel Food Catalogue and RASFF operate, and the costs of Novel Food applications.
This report also includes a 1-hour consultation call with CBD-Intel’s analyst team.